This journal article is a practice guideline that provides recommendations summarizing the growing literature and current best practices of chronic Hepatitis C Virus (HCV) treatment, including treatment in difficult-to-treat populations. These recommendations are based on an extensive review of published data, national consensus recommendations, and input from thought leaders involved in HCV care and treatment.
This poster is to be used as a pocket resource contains photographs and agents for treatment of oral manifestations of HIV disease including: antifungal, antiviral, topical, antibacterial, and other treatments.
This report provides updated uniform criteria for use by public health professionals when reporting the nationally notifiable infectious diseases listed in Part One of this report. A revision date is included for case definitions that have been revised. The case definitions for some infectious conditions not designated as nationally notifiable are included in Part Two of this report.
This report, for health professionals, government agencies, and organizations, presents information about HIV/AIDS and TB. It provides epidemiological statistics concerning the relationship between HIV/AIDS and TB, including incidence, morbidity rates, and mortality rates. It discusses TB and HIV transmission, how HIV can facilitate the development of active TB, and recommendations for the prevention of TB among HIV-positive persons.
This report describes approaches for managing patients with TB who are candidates for or who are undergoing protease inhibitor therapy and presents interim recommendations for managing these patients until additional data are available and formal guidelines are issued. Protease inhibitors interact with rifamycin derivatives, which are used to treat and prevent the mycobacterial infections commonly observed in patients with the HIV. The report provides background information on the management of TB and the three treatment options currently available for these patients.
